Hepatorenales Syndrom und zirrhotische Kardiomyopathie

• Literatur

• 1 EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417
• 2 Arroyo V, Gines P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-176
• 3 Piano S, Rosi S, Maresio G et al. Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol 2013; 59: 482-489
• 4 Salerno F, Gerbes A, Gines P et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-1318
• 5 Gerbes AL, Gulberg V, Sauerbruch T et al. [German S3-guideline „Ascites, spontaneous bacterial peritonitis, hepatorenal syndrome“]. Z Gastroenterol 2011; 49: 749-779
• 6 Wong F, Nadim MK, Kellum JA et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011; 60: 702-709
• 7 Moreau R, Jalan R, Gines P et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144: 1426-1437, 37e1-9
• 8 Martin-Llahi M, Guevara M, Torre A et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 2011; 140: 488-496 e4
• 9 Gines A, Escorsell A, Gines P et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-236
• 10 Verna EC, Wagener G. Renal interactions in liver dysfunction and failure. Curr Opin Crit Care 2013; 19: 133-141
• 11 Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279-1290
• 12 Park SW, Kim M, Brown KM et al. Paneth cell-derived interleukin-17A causes multiorgan dysfunction after hepatic ischemia and reperfusion injury. Hepatology 2011; 53: 1662-1675
• 13 Mandorfer M, Bota S, Schwabl P et al. Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 2014; 146: 1680-1690 e1
• 14 Serste T, Francoz C, Durand F et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol 2011; 55: 794-799
• 15 Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis 2011; 58: 928-938
• 16 Restuccia T, Ortega R, Guevara M et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004; 40: 140-146
• 17 Sanyal AJ, Boyer T, Garcia-Tsao G et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-1368
• 18 Gerbes AL, Huber E, Gulberg V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology 2009; 137: 1179 ; author reply 1181
• 19 Nazar A, Pereira GH, Guevara M et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2010; 51: 219-226
• 20 Martin-Llahi M, Pepin MN, Guevara M et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 1352-1359
• 21 Singh V, Ghosh S, Singh B et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 2012; 56: 1293-1298
• 22 Nassar Junior AP, Farias AQ, D’Albuquerque LA et al. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One 2014; 9: e107466
• 23 Rossle M. TIPS: 25 years later. J Hepatol 2013; 59: 1081-1093
• 24 Mitzner SR, Stange J, Klammt S et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-286
• 25 Gonwa TA, Morris CA, Goldstein RM et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome – experience in 300 patients. Transplantation 1991; 51: 428-430
• 26 Lafayette RA, Pare G, Schmid CH et al. Pretransplant renal dysfunction predicts poorer outcome in liver transplantation. Clin Nephrol 1997; 48: 159-164
• 27 Wong F, Leung W, Al Beshir M et al. The outcome of patients with cirrhosis and Type-1 hepatorenal syndrome treated with liver transplantation. Liver Transpl 25.11.2014; [Epub ahead of print]
• 28 Fischer L, Klempnauer J, Beckebaum S et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation – PROTECT. Am J Transplant 2012; 12: 1855-1865
• 29 Zardi EM, Abbate A, Zardi DM et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol 2010; 56: 539-549
• 30 Pellicori P, Torromeo C, Calicchia A et al. Does cirrhotic cardiomyopathy exist? 50 years of uncertainty. Clin Res Cardiol 2013; 102: 859-864
• 31 Wiese S, Hove JD, Bendtsen F et al. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol 2014; 11: 177-186
• 32 Nazar A, Guevara M, Sitges M et al. LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. J Hepatol 2013; 58: 51-57
• 33 Ortiz-Olvera NX, Castellanos-Pallares G, Gomez-Jimenez LM et al. Anatomical cardiac alterations in liver cirrhosis: an autopsy study. Ann Hepatol 2011; 10: 321-326
• 34 Wehmeyer MM, Heuer AS, Benten D et al. High rate of cardiac abnormalities in post-mortem analysis of patients suffering from liver cirrhosis. Journal of Clinical Gastroenterology 2015; (in press)
• 35 Moller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008; 57: 268-278
• 36 Ward CA, Liu H, Lee SS. Altered cellular calcium regulatory systems in a rat model of cirrhotic cardiomyopathy. Gastroenterology 2001; 121: 1209-1218
• 37 Bortoluzzi A, Ceolotto G, Gola E et al. Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms. Hepatology 2013; 57: 266-276
• 38 Ruiz-del-Arbol L, Achecar L, Serradilla R et al. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine. Hepatology 2013; 58: 1732-1741
• 39 Kazankov K, Holland-Fischer P, Andersen NH et al. Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver Int 2011; 31: 534-540
• 40 Cazzaniga M, Salerno F, Pagnozzi G et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut 2007; 56: 869-875
• 41 Saner FH, Neumann T, Canbay A et al. High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients. Transpl Int 2011; 24: 425-432
• 42 Henriksen JH, Bendtsen F, Hansen EF et al. Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis. J Hepatol 2004; 40: 239-246